How Gilgamesh landed a $1.2B AbbVie deal in psychedelics: Business podcast on negotiation, IP, and clinical strategy

Psychedelics startup Gilgamesh is the focus of a podcast episode about landing a $1.2B deal with AbbVie, framed as a business and translational-innovation win. The episode centers on what made the partnership attractive to a large pharma company, including deal positioning, asset value, and how Gilgamesh built credibility in the psychedelics space. It connects psychedelics research to commercial execution by discussing how early pipeline and strategy can translate into major funding and corporate collaboration, highlighting what matters for commercialization in this sector.